U.S.-listed shares of Novo Nordisk sank in premarket trading Tuesday after the Danish drugmaker cut its full-year outlook and ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...

Novo Nordisk ( NVO) continued its downward spiral and fell 3.8% in premarket trade, a day after the Danish drugmaker slashed ...

Investing.com - Novo Nordisk (NYSE:NVO)’s weight-loss and diabetes drugs Wegovy and Ozempic could face increased pressure in the future, weighing on the Danish pharmaceutical group’s earnings, ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, on Tuesday ...

Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a new chief executive, who highlighted the “urgency” of the moment.

In April, Danish drugmaker Novo Nordisk formed what was supposed to be a long-term collaboration to promote its weight-loss ...

Join Ramzan Karmali as he takes a closer look at today's Trending stock Tickers - Adidas, the sportswear giant - Novo Nordisk, the creators of Ozempic and Starbucks, the coffee chain.